Safety and Immunogenicity of adenovirus vector COVID-19 vaccines for radiotherapy patients in Thailand

Recruiting

• Conditions: What are the immunization and safety effects of the COVID-19 adenovirus vector Astrazenaca vaccine in irradiated patients in Thailand?; radiation, covid-19, vaccine

• Registration Number: TCTR20210921002
• Lead Sponsor: King Chulalongkorn Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-21
• Study Completion: 2022-11-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1) Age greater than or equal to 18 years
2) ECOG Performance status 0-2
3) Well-controlled underlying disease
4) Life expectancy 6 months or more
5) was diagnosed with a solid cancer or a tumor that requires radiation therapy or radiation in combination with chemotherapy drugs with at least 10 radiation plans
6) Voluntarily receive the Astrazeneca COVID-19 vaccine.
7) Voluntarily join the program with written consent.

Exclusion Criteria

1) Immunodeficiency conditions such as HIV infection or congenital immunodeficiency syndrome
2) A history of COVID-19 infection or a nucleocapsid protein IgG antibodies test before the first dose of vaccination has a positive result indicating a natural infection.
3) There is a radiation plan for total body irradiation (TBI), total lymphoid irradiation (TLI), craniospinal irradiation (CSI).
4) Receive chemotherapy drugs taken before radiation within 4 weeks (induction or palliative chemotherapy).
5) have received radiation before (previous radiotherapy)
6) Pregnant women

Study & Design

• Study Type: Observational
• Study Design: Not specified